Back to top

Corvus announces IND application approved by CDE of China NMPA to start trial

Corvus Pharmaceuticals (CRVS) announced that the IND application submitted by its partner in China, Angel Pharmaceuticals, has been approved by the...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Corvus Pharmaceuticals, Inc. (CRVS)